drugset / Trial / NCT03164980
QoL-Comparison Between Trabectedin/PLD and Pt-based Therapy in Patients With Pt-sensitive Recurrent Ovarian Cancer
Phase 4
Terminated
89 enrolled
North Eastern German Society of Gynaecological Oncology
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · collabPharmaMar · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter, randomized, controlled, open-label study including patients with recurrent, platinum-sensitive, ovarian, peritoneal or fallopian tube cancer. The main scope of the trial is to evaluate QoL during chemotherapy comparing trabectedin/PLD with other standard platinum-based chemotherapy in platinum-sensitive disease.
Timeline
- Start
- 2018-02-01
- Primary completion
- 2023-08-08
- Completion
- 2023-08-08
Outcome
Outcome not reported
Stopped (Enrollment): “A total of 204 patients were planned to be randomized. Due to slow recruitment of the trial, the recruitment was prematurely terminated after randomization of the 89th patient.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trabectidin | Unknown | — | — |